The results of the open observational, international, multicenter, prospective program to assess the efficacy, safety and tolerability of the first direct renin inhibitor RasilezR (aliskiren) in patients with arterial hypertension in ‘real-life’ clinical practice settings (DRIve)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.